NATURES SUNSHINE PRODUCTS INC
NATR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NATR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NATR
Nature's Sunshine Products Inc. (NATR) is a global manufacturer and direct seller of herbal and nutritional supplements, reporting $117.0M in revenue and $3.5M net income for the quarter ended June 30, 2026.
Key risk: Economic downturn impact
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$250.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for NATURES SUNSHINE PRODUCTS INC.
Nature's Sunshine Products Inc. (NATR) is a global manufacturer and direct seller of herbal and nutritional supplements, reporting $117.0M in revenue and $3.5M net income for the quarter ended June 30, 2026.
- Global manufacturer and direct seller of high-quality herbal and nutritional supplements [sec_mda · as of 2026-03-10].
- Reported net sales of $480.1 million and net income of $20.5 million for fiscal 2025 [sec · filed 2026-03-27].
- Cash and cash equivalents of $82.5M as of June 30, 2026, with working capital of $109.7 million [sec_mda · as of 2026-08-06].
- No outstanding balances under its revolving credit agreements as of September 30, 2025 [sec_mda · as of 2025-11-06].
What works
- Consistent revenue growth trajectory, with net sales increasing from $445.3 million in 2023 to $480.1 million in 2025 [sec · filed 2024-03-15][sec · filed 2026-03-27].
- Strong liquidity position with $82.5M in cash and $109.7M working capital as of June 30, 2026, and no debt on revolving credit facilities [sec_mda · as of 2026-08-06][sec_mda · as of 2025-11-06].
- Management believes cash from operations and available cash will be sufficient to fund normal operating needs on both a short- and long-term basis [sec_mda · as of 2026-08-06].
What to weigh
- A prolonged economic downturn or decrease in product demand could adversely affect long-term liquidity [sec_mda · as of 2026-08-06].
- A significant portion of cash ($84.0M of $87.6M as of March 31, 2026) is held in foreign markets and may be subject to withholding taxes and repatriation restrictions [sec_mda · as of 2026-05-07].
- Unfavorable settlement of unrecognized tax positions or non-income tax contingencies could negatively impact liquidity [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
2025 net sales and net income
“$480.1 Million | $20.5 Million | $48.7* Million | $259.38**”
SEC filings · March 27, 2026
Cash and working capital as of June 30, 2026
“As of June 30, 2026, working capital was $109.7 million”
SEC MD&A · August 6, 2026
Company description
“We are a global leader in manufacturing and marketing high-quality herbal and nutritional su”
SEC MD&A · March 10, 2026
No outstanding debt on credit facilities
“At September 30, 2025, there were no outstanding balances under the Credit Agreement or the Capital Credit Agreement.”
SEC MD&A · November 6, 2025
Risks & what to watch (3)›
Key risks
- Economic downturn impact — Prolonged economic downturn or decreased product demand could adversely affect liquidity [sec_mda · as of 2026-08-06].
- Foreign cash repatriation risk — Most cash held abroad may be subject to withholding taxes and restrictions before use in U.S. [sec_mda · as of 2026-05-07].
- Tax contingencies — Unfavorable settlement of unrecognized tax positions or non-income tax contingencies could hurt liquidity [sec_mda · as of 2026-08-06].
What to watch
- Monitor quarterly revenue and net income trends to assess growth trajectory [sec · filed 2026-03-27].
- Watch for any changes in foreign cash repatriation policies or tax liabilities that could affect liquidity [sec_mda · as of 2026-05-07].
- Track any new share repurchase authorizations or debt activity under the revolving credit facility [sec_mda · as of 2025-11-06].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run NATURES SUNSHINE PRODUCTS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NATURES SUNSHINE PRODUCTS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
OCF $835K · Net income $4M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
14 buys · 8 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
150
Total value held
$262.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,193,666 | $28.6M |
| blackrock, inc. | 1,064,454 | $25.5M |
| dimensional fund advisors lp | 895,437 | $21.5M |
| kennedy capital management llc | 691,498 | $16.6M |
| american century companies inc | 574,825 | $13.8M |
| renaissance technologies llc | 531,924 | $12.8M |
| geode capital management, llc | 372,549 | $8.9M |
| punch & associates investment management, inc. | 340,000 | $8.2M |
| state street corp | 325,805 | $7.8M |
| hillsdale investment management inc. | 316,867 | $7.6M |
Showing top 10 of 150 institutional holders of NATURES SUNSHINE PRODUCTS INC. Open the full 13F history after sign-in.
Short Interest
as of May 13, 2026- % of float
- 2.1%
- Days to cover
- 3.4
- Shares short
- 269,513
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NATR short interestGovernance
Frequently asked questions
What is the AI investment thesis for NATURES SUNSHINE PRODUCTS INC?
Nature's Sunshine Products Inc. (NATR) is a global manufacturer and direct seller of herbal and nutritional supplements, reporting $117.0M in revenue and $3.5M net income for the quarter ended June 30, 2026.
Who is the CEO of NATURES SUNSHINE PRODUCTS INC?
Mr. Kenneth G. Romanzi is the chief executive officer of NATURES SUNSHINE PRODUCTS INC (NATR).
Where is NATURES SUNSHINE PRODUCTS INC headquartered?
NATURES SUNSHINE PRODUCTS INC (NATR) is headquartered in Lehi, UT, United States.
What therapeutic areas does NATURES SUNSHINE PRODUCTS INC focus on?
NATURES SUNSHINE PRODUCTS INC develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.